A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
AUTOR(ES)
Rubin, Joshua B.
FONTE
National Academy of Sciences
RESUMO
The vast majority of brain tumors in adults exhibit glial characteristics. Brain tumors in children are diverse: Many have neuronal characteristics, whereas others have glial features. Here we show that activation of the Gi protein-coupled receptor CXCR4 is critical for the growth of both malignant neuronal and glial tumors. Systemic administration of CXCR4 antagonist AMD 3100 inhibits growth of intracranial glioblastoma and medulloblastoma xenografts by increasing apoptosis and decreasing the proliferation of tumor cells. This reflects the ability of AMD 3100 to reduce the activation of extracellular signal-regulated kinases 1 and 2 and Akt, all of which are pathways downstream of CXCR4 that promote survival, proliferation, and migration. These studies (i) demonstrate that CXCR4 is critical to the progression of diverse brain malignances and (ii) provide a scientific rationale for clinical evaluation of AMD 3100 in treating both adults and children with malignant brain tumors.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=263845Documentos Relacionados
- T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure
- A small-molecule switch for Golgi sulfotransferases
- Novel Small-Molecule Inhibitors of RNA Polymerase III
- A small-molecule approach to studying invasive mechanisms of Toxoplasma gondii
- A systematic method for identifying small-molecule modulators of protein–protein interactions